|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 22, 2018 ) Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2018, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.
Report Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2376449
The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 10, 39, 20, 2, 75, 19 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.
Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to buy:
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2376449
Key Players:
AB Science SA
Ache Laboratorios Farmaceuticos SA
Adamis Pharmaceuticals Corp
Advanced Inhalation Therapies (AIT) Ltd
AlgiPharma AS
Allinaire Therapeutics LLC
Angiocrine Bioscience Inc
apceth Biopharma GmbH
Aridis Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
AusBio Ltd
Bioneer Corp
BioStem Technologies Inc
Boehringer Ingelheim GmbH
C4X Discovery Holdings PLC
Celon Pharma SA
Chiesi Farmaceutici SpA
China Resources Pharmaceutical Group Ltd
Cipla Ltd
Circassia Pharmaceuticals Plc
CSL Ltd
Cytokinetics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Denovo Biopharma LLC
Diffusion Pharmaceuticals Inc
Domainex Ltd
Enterprise Therapeutics Ltd
Errant Gene Therapeutics LLC
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd
Galapagos NV
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Grifols SA
Hanmi Pharmaceuticals Co Ltd
iCeutica Inc
Icure Pharmaceutical Inc
InMed Pharmaceuticals Inc
Insmed Inc
Intech Biopharm Ltd
Invion Ltd
Johnson & Johnson
KBP BioSciences Co Ltd
Kissei Pharmaceutical Co Ltd
Kyowa Hakko Kirin Co Ltd
MedImmune LLC
Mereo Biopharma Group Plc
Meridigen Biotech Co Ltd
Novartis AG
Octapharma AG
OncBioMune Pharmaceuticals Inc
OPKO Health Inc
Orchid Pharma Ltd
Orion Corp
Pfizer Inc
PharmaLundensis AB
Pharmaxis Ltd
Promedior Inc
ProMetic Life Sciences Inc
Pulmatrix Inc
Qu Biologics Inc
Quark Pharmaceuticals Inc
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Resolys Bio Inc
Respira Therapeutics Inc
Respiratorius AB
rEVO Biologics Inc
Rhizen Pharmaceuticals SA
SATT North SAS
SolAeroMed Inc
sterna biologicals GmbH & Co KG
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Synairgen Plc
Synovo GmbH
Syntrix Biosystems Inc
Therabron Therapeutics Inc
Theravance Biopharma Inc
Torrent Pharmaceuticals Ltd
Unity Biotechnology Inc
Unizyme Laboratories AS
Verona Pharma Plc
Yungjin Pharm Co Ltd
Zai Lab Ltd
Get More Information about this Report@ http://www.orbisresearch.com/reports/index/chronic-obstructive-pulmonary-disease-copd-pipeline-review-h2-2018
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
